tbuckley/cabot-search huggingface dataset:
Minimal residual disease by flow cytometry at the end of chemotherapy for remission induction in pediatric patients with acute lymphoblastic leukemia: Experience from a center in a low-income country.
Authors: Eloy Perez, Primo Cruz-Borja, Silvia Chavez-Gallegos
Journal: Journal of Clinical Oncology (2012)

9554 Background: The presence of minimal residual disease (MDR) following therapy for acute lymphoblastic leukemia (ALL) has been shown to be an important prognostic marker in many studies. MRD is typically detected either by polymerase chain reaction amplification or by flow cytometry. Flow-based MRD assessment has the potential for rapidly identifying patients at increased risk of relapsed, allowing for prompt changes in therapy, including earlier intensification. There are not many information about the response by MRD in countries with limited resources. Methods: The patients included were 90 ALL patients treated at the Hospital Infantil de Morelia from June 1, 2009 to January 5, 2012. MRD positivity (+) was defined as &gt;0.01% of the gated population. Results: MRD was obtained in 90 patients, 38 males and 36 females. The median age was 7 years (10 months to 15 years). The levels of MRD were: &lt;0.01, 74 (82.2%), 0.01-1%, 9 (10%), ≥1%, 7 (7.7%). There was not a statistically significant association between the most important ALL prognostic factors (Gender, Age at diagnosis, White blood cell count at diagnosis, Central Nervous System disease, Prednisone response, DNA Index, Immunophenotype). Conclusions: The good response found is similar to that reported by international groups, a situation which suggests that the response to chemotherapy is appropriate. However, cure rates are still not equal making it necessary to review institutional treatment protocols and social characteristics of the population to achieve cure rates reported by international groups.
Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Simultaneous Inhibition of the Raf/MEK/ERK and BCL-2 Pathways
Authors: Maria Rosaria Ricciardi, Michele Milella, Francesco Libotte, Elisabetta Calabrese, Paola Bergamo, Sara Santinelli, Samantha Decandia, Cinzia De Benedictis, Anna Levi, Robert Foà, Agostino Tafuri, Maria Teresa Petrucci
Journal: Blood (2008)
Which Patients With Rheumatoid Arthritis Will Start Biologics, How Soon, and Why—Much to Learn From a Universal Coverage Setting
Authors: Natalie McCormick
Journal: JAMA Network Open (2019)

Mark Tatangelo, BA; George Tomlinson, PhD; J. Michael Paterson, MSc; Vandana Ahluwalia, MD, FRCPC; Alex Kopp, BA; Tara Gomes, PhD; Nick Bansback, PhD; Claire Bombardier, MD, FRCPC
Abstract 18677: Increased Disease Complexity and Resource Utilization Among Heart Failure Related Visits in the Emergency Department From 2007-2014
Authors: Heather Griffis, Lihai Song, Erika J Mejia, Matthew J O'Connor, Kimberly Y Lin, Christopher E Mascio, Pirouz Shamszad, Aaron Donoghue, Chitra Ravishankar, Robert E Shaddy, Joseph W Rossano
Journal: Circulation (2017)

Introduction: With increasing health care costs, complex conditions such as heart failure (HF) are becoming more resource intensive. The epidemiology of HF among pediatric patients is relatively unknown, as well as associated resource utilization. This vulnerable population is complex, with many associated comorbidities. Hypothesis: We aimed to test the hypothesis that complex chronic conditions and resource utilization among pediatric heart failure related (HFR) emergency department (ED) visits has increased over time in a nationally representative dataset. Methods: The National Emergency Department Survey (NEDS) is a nationally representative sample of approximately 135 million emergency department visits across the United States from 2007-2014. Pediatric HFR patient visits were identified via age (&lt;18 years) and ICD-9 codes for heart failure. Complex chronic conditions were coded for 7 common diagnosis groups. Demographic and clinical characteristics are reported. Sample weights are used respective to each year of data. Results: The number of HFR ED visits was stable over time with 5233 in 2007 to 4656 in 2014. In 2014, the mean age of these patients was 4.9 years(SE 0.2), 48%(SE 1.6) were females, and CHD was the diagnosis in 45%(SE 1.6), and cardiomyopathy in 10%(SE 1.0). The most common chronic condition (other than cardiac/congenital or genetic) was gastrointestinal (17.0%), followed by neuromuscular (7.9%) and metabolic (6.8%). The proportion of HFR ED visits with 3 or more complex chronic conditions rose from 12.4% in 2007 to 18.1% in 2014. Median total charges for HFR ED visit increased by 47% between 2007 to 2014 [$1296 (CI 1243-1349) to $1908 (CI 1766-2055), respectively]. For HF patients with 3+ complex chronic conditions, mean total charges increased 79% from $1360(SE 101) to $2434(SE 182). Conclusions: While the total HFR ED visits over the decade from 2007 to 2014 remained stable, the proportion of pediatric HFR ED visits with complex chronic conditions increased along with charges associated with care. These results highlight the increasing complexity of pediatric HF patients and the need for further study to develop optimal care models in this challenging population.
Environmental and genetic risk factors of eczema phenotypes
Authors: C. Hu, L. Duijts, N.S. Erler, N.J. Elbert, C. Piketty, V. Bourdès, S. Blanchet‐Réthoré, J.C. Jongste, S.G.M.A. Pasmans, J.F. Felix, T. Nijsten
Journal: British Journal of Dermatology (2019)

Eczema is an itchy skin disease affecting up to 25% of children worldwide and is variable in onset (when it starts) and persistence (how long it lasts for). There is a need to define more detailed eczema types, called phenotypes, to better predict each type's natural course and understand its specific underlying risk factors. Subsequently, the onset and worsening of eczema could be prevented. In a population-based Dutch group of 5,297 multi-ethnic children, five eczema phenotypes were identified based on their probability, taking into account the age of onset and course of eczema between birth and the age of 10 years. The identified eczema phenotypes were never (76%), early transient (8%), mid-transient (6%), late transient (8%) and persistent eczema (2%). Children with early, mid- and late transient eczema had a high probability of developing eczema before the age of 2 years, around the age of 2 years and 5 years, respectively, after which the eczema gradually disappeared. Children with persistent eczema had a high probability of eczema from birth until the age of 10 years. The eczema phenotypes model seemed valid for a multi-ethnic population in an ever-globalizing world. Previously known eczema risk factors (including socio-economic, lifestyle, or genetic factors related to skin barrier defects and immune system) differentiated to a limited degree between the different phenotypes. Early transient eczema was most common in males only. Children with late transient or persistent eczema were more often of Asian and African ethnicity. Therefore, sex and ethnicity could be useful for prediction purposes. Further studies, ideally in a ‘hypothesis free approach’, are needed to identify other possible predictive factors for the development of eczema phenotypes, in order to improve eczema management and prevention strategies.
Multicentre, cross-sectional study of ventricular arrhythmias in chronically haemodialysed patients
Authors: B. Redaelli, A. Cavalli, R. Latini, A. P. Maggioni, G. Mingardi, G. Osculati, S. Sforzini, G. Tognoni, A. Vincenti, A. Volpi, L. Conforti, L. Gondoni, E. Santoro, M. Rocchetti
Journal: The Lancet (1988)
Optimizing Management of Patients With Barrett’s Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling
Authors: Amir-Houshang Omidvari, Ayman Ali, William D. Hazelton, Sonja Kroep, Minyi Lee, Steffie K. Naber, Brianna N. Lauren, Sassan Ostvar, Ellen Richmond, Chun Yin Kong, Joel H. Rubenstein, Iris Lansdorp-Vogelaar, Georg Luebeck, Chin Hur, John Inadomi
Journal: Clinical Gastroenterology and Hepatology (2019)
老年人走路慢的预测价值 提示与血管疾病病死率有关，也可能预测体弱
Authors: Rowan, Harwood, Simon, Conroy, 王翠娣
Journal: BMJ (2010)

走路快的人比走路慢的更长寿，患有血管疾病者更是如此。根据一项前瞻性队列研究（doi：10．1136／bmj．b4460），Dumurgier和同仁们通过对3208名相对健康的老年人进行步速测定（至少测6米长距离），并随访了5年，证实了此观点的正确性。步速取决于身体状况，如年龄、性别、身高、有无疾病以及体质等。
Targeting treatable traits in severe asthma: a randomised controlled trial
Authors: Vanessa M. McDonald, Vanessa L. Clark, Laura Cordova-Rivera, Peter A.B. Wark, Katherine J. Baines, Peter G. Gibson
Journal: European Respiratory Journal (2019)

Rationale Treatable traits have been proposed as a new paradigm for airway disease management. Objectives To characterise treatable traits in a severe asthma population and to determine the efficacy of targeting treatments to these treatable traits in severe asthma. Methods Participants (n=140) with severe asthma were recruited to a cross-sectional study and underwent a multidimensional assessment to characterise treatable traits. Eligible participants with severe asthma (n=55) participated in a 16-week parallel-group randomised controlled trial to determine the feasibility and efficacy of management targeted to predefined treatable traits, compared to usual care in a severe asthma clinic. The patient-reported outcome of health-related quality of life was the trial's primary end-point. Main results Participants with severe asthma had a mean± sd of 10.44±3.03 traits per person, comprising 3.01±1.54 pulmonary and 4.85±1.86 extrapulmonary traits and 2.58±1.31 behavioural/risk factors. Individualised treatment that targeted the traits was feasible and led to significantly improved health-related quality of life (0.86 units, p&lt;0.001) and asthma control (0.73, p=0.01). Conclusions Multidimensional assessment enables detection of treatable traits and identifies a significant trait burden in severe asthma. Targeting these treatable traits using a personalised-medicine approach in severe asthma leads to improvements in health-related quality of life, asthma control and reduced primary care acute visits. Treatable traits may be an effective way to address the complexity of severe asthma.
Photoelectric Cardiac Pacing by Flexible and Degradable Amorphous Si Radial Junction Stimulators
Authors: Zongguang Liu, Bin Wen, Luyao Cao, Shaobo Zhang, Yakui Lei, Guangzhi Zhao, Long Chen, Junzhuan Wang, Yi Shi, Jun Xu, Xiangbin Pan, Linwei Yu
Journal: Advanced Healthcare Materials (2019)

Implanted pacemakers are usually bulky and rigid electronics that are constraint by limited battery lifetimes, and need to be installed and repaired via surgeries that risk secondary infection and injury. In this work, a flexible self-powered photoelectric cardiac stimulator is demonstrated based on hydrogenated amorphous Si (a-Si:H) radial p-i-n junctions (RJs), constructed upon standing Si nanowires grown directly on aluminum thin foils. The flexible RJ stimulators, with an open-circuit voltage of 0.67 V and short-circuit current density of 12.7 mA cm-2 under standard AM1.5G illumination, can be conformally attached to the uneven tissue surface to pace heart-beating under modulated 650 nm laser illumination. In vivo pacing evaluations on porcine hearts show that the heart rate can be effectively controlled by the external photoelectric stimulations, to increase from the normal rate of 101-128 beating min-1 . Importantly, the a-Si:H RJ units are highly biofriendly and biodegradable, with tunable lifetimes in phosphate-buffered saline environment controlled by surface coating and passivation, catering to the needs of short term or lasting cardiac pacing applications. This implantable a-Si:H RJ photoelectric stimulation strategy has the potential to establish eventually a self-powered, biocompatible, and conformable cardiac pacing technology for clinical therapy.
介入心脏病学基本知识（二）——治疗心动过速的植入型装置
Authors: TimothyHoughton, GerryCKaye, 唐恺, 张澍
Journal: BMJ (2005)

对心动过速的起搏治疗已经获得成功。它在治疗室上性心动过速(室上速）片面的表现尤其引人瞩目，而用起搏来终止室性心动过速（室速）则一直较为困难。但随着人们对室性心律失常机理（mechanism）的认识，加之起搏器功能的日益完善．最终使心腔内起搏与心腔内电击技术结合到了一起，从而使植入型心律转复除颤器(implaniable cardioverter defibrillalors，ICD)得以问世。
A Screening and Intervention Program Reducing Mortality and Serious Morbidity Associated with Neonatal Alloimmune Thrombocytopenia.
Authors: Jens Kjeldsen-Kragh, Mette K. Killie, Geir Tomter, Elzbieta Golebiowska, Helene Pedersen, Ingrid Randen, Reidun Hauge, Berit Aune, Pal Oian, Lauritz B. Dahl, Jouko Pirhonen, Leif Svenningsen, Hakon Wergeland, Rolf Lindeman, Henrik Husby, Morten Gronn, Bjorn Skogen, Anne Husebekk
Journal: Blood (2005)
Antagonism between HTRA3 and TGFβ1 Contributes to Metastasis in Non–Small Cell Lung Cancer
Authors: Jingya Zhao, Mingxiang Feng, Dong Liu, Haixia Liu, Mengmeng Shi, Jing Zhang, Jieming Qu
Journal: Cancer Research (2019)

High temperature requirement A3 (HTRA3, long and short isoforms) is a member of the HtrA family and has been implicated as a tumor suppressor in cancer progression in multiple cancer types, yet its molecular functions in non-small cell lung cancer (NSCLC) are not well understood. Here, we report that decreased levels of HTRA3 negatively correlate with elevated TGFβ1 in lung tumor tissue with metastasis. Furthermore, high expression of HTRA3 indicated better prognosis independent of TGFβ1 expression. In NSCLC cell lines, exogenous TGFβ1 significantly downregulated the level of HTRA3, especially the long isoform, during induction of epithelial-mesenchymal transition (EMT). Mechanistically, c-Jun, which is elevated by TGFβ1, directly bound the promoter of HTRA3-L and inhibited its transcription. As a negative feedback loop, overexpression of HTRA3-L attenuated TGFβ1-mediated invasion-metastasis cascades via activation of SMAD2/3 and sensitized cells to anti-PD-L1 treatment. Taken together, our findings suggest that in the early stages of cancer, overexpressed HTRA3 acts as a brake on the oncogenic effects of TGFβ1 and inhibits tumor metastasis. In later stages, the role of HTRA3 is weakened and TGFβ1 efficiently promotes EMT in the absence of the HTRA3 brake. SIGNIFICANCE: This study provides new mechanistic insight of the interaction between HTRA3 and TGFβ in lung cancer by illustrating that HTRA3 is a novel mediator acting as a suppressor of TGFβ1-related oncogenic effects.
PTPN13 induces cell junction stabilization and inhibits mammary tumor invasiveness
Authors: Mohamed Hamyeh, Florence Bernex, Romain M. Larive, Aurélien Naldi, Serge Urbach, Joelle Simony-Lafontaine, Carole Puech, William Bakhache, Jérome Solassol, Peter J. Coopman, Wiljan J.A.J Hendriks, Gilles Freiss
Journal: Theranostics (2019)

Clinical data suggest that the protein tyrosine phosphatase PTPN13 exerts an anti-oncogenic effect. Its exact role in tumorigenesis remains, however, unclear due to its negative impact on FAS receptor-induced apoptosis. Methods: We crossed transgenic mice deleted for PTPN13 phosphatase activity with mice that overexpress human HER2 to assess the exact role of PTPN13 in tumor development and aggressiveness. To determine the molecular mechanism underlying the PTPN13 tumor suppressor activity we developed isogenic clones of the aggressive human breast cancer cell line MDA-MB-231 overexpressing either wild type or a catalytically-inactive mutant PTPN13 and subjected these to phosphoproteomic and gene ontology analyses. We investigated the PTPN13 consequences on cell aggressiveness using wound healing and Boyden chamber assays, on intercellular adhesion using videomicroscopy, cell aggregation assay and immunofluorescence. Results: The development, growth and invasiveness of breast tumors were strongly increased by deletion of the PTPN13 phosphatase activity in transgenic mice. We observed that PTPN13 phosphatase activity is required to inhibit cell motility and invasion in the MDA-MB-231 cell line overexpressing PTPN13. In vivo, the negative PTPN13 effect on tumor invasiveness was associated with a mesenchymal-to-epithelial transition phenotype in athymic mice xenografted with PTPN13-overexpressing MDA-MB-231 cells, as well as in HER2-overexpressing mice with wild type PTPN13, compared to HER2-overexpressing mice that lack PTPN13 phosphatase activity. Phosphoproteomic and gene ontology analyses indicated a role of PTPN13 in the regulation of intercellular junction-related proteins. Finally, protein localization studies in MDA-MB-231 cells and HER2-overexpressing mice tumors confirmed that PTPN13 stabilizes intercellular adhesion and promotes desmosome formation. Conclusions: These data provide the first evidence for the negative role of PTPN13 in breast tumor invasiveness and highlight its involvement in cell junction stabilization.
Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias
Authors: Janet L. Kwiatkowski, Mohsen Saleh Elalfy, Caroline Fradette, Mona Hamdy, Amal El-Beshlawy, Fatma Soliman Elsayed Ebeid, Monica PINHEIRO DE ALMEIDA Verissimo, Mohamed Ahmed Badr, Alshehri Abdulrahman, Julie Kanter, Baba PD Inusa, Mohamed Bejaoui, Suzan Williams, Yurdanur Kilinc, Yu-Chung Tsang, Anne Stilman, Anna Rozova, Jodie Sinclair, Dian Shaw, Theresa Chan, Noemi Toiber Temin, David Lee, Michael Spino, Fernando Tricta
Journal: Blood (2019)
Outcome of Transplant-Eligible Patients with Hodgkin Lymphoma with An Inadequate Response to Second Line Chemotherapy with Gemcitabine, Dexamethasone, Cisplatin (GDP).
Authors: Tara Seshadri, Christine Massey, Noemi Puig, Armand Keating, Michael Crump, John Kuruvilla
Journal: Blood (2008)
Content validity of signs and symptoms measures with the EORTC core module in women with locally advanced or metastatic breast cancer (MBC): A phase II trial with eribulin mesylate.
Authors: W. Robert Simons
Journal: Journal of Clinical Oncology (2013)

e17576 Background: The EORTC-QLQ30 is the core quality of life (QOL) instrument developed by the European Organization for Research and Treatment in Cancer. We assessed content validity for the signs and symptoms component in an investigational trial. Methods: We use a Phase II clinical trial where 291 women with locally advanced or MBC were required to have received prior treatment with an anthracycline, a taxane, and capecitabine. EORTC-QLQ30 was collected every second cycle, before drug administration and before patients were informed of their tumor assessment. We use the reported adverse events (AE) for those signs and symptoms to test the correlation between reported AEs and responses to the QoL questionnaire. The sum of the incidence by patient is generated as well as average scores for each sign and symptom. An endpoint for respondents positively reporting signs and symptoms without any AE is also evaluated (False-Positive). Statistically significant positive correlations between AEs and signs and symptoms as well as negative correlations for False-Positive establish content validity. Results: 283 women provided 1068 QOL assessments. Their general health status was 68.88 (P&lt;0.0001) on a 100 point scale, improving by 7.90 (P=0.0153) when responding to eribulin. Nausea and vomiting were positively correlated with the reported incidence of nausea as AEs, 0.126 (P=0.03) and vomiting (P&lt;0.01); false positives were negatively correlated, (-0.329; P&lt;0.01 and -0.352; P&lt;0.01, respectively). Constipation also satisfied the criteria for content validity, 0.189 (P&lt;0.01) for correspondence and (-0.394; P&lt;0.01) for lack of False-Positives. Diarrhea had a correspondence of 0.292 (P&lt;0.01) and specificity of (-0.260; P&lt;0.01). Dyspnea had a 0.226 (P&lt;0.01) correspondence and (-0.349; P&lt;0.01) specificity. Insomnia failed the criteria. Upset by hair loss was weakly correlated with alopecia but very specific (-0.479; P&lt;0.01). Conclusions: Signs and symptoms as measured by the EORTC-QLQ-BR32 questionnaire have content validity in an investigational setting and they contribute clinically meaningful information to reported AE incidence data. Clinical trial information: NCT00246090.
Abstract 12299: Cardiovascular Stroke Nursing Best Abstract Award: Can Adverse Social Determinants of Health be Overcome by Cardiovascular Risk Reduction Interventions Designed Specifically for Rural Socioeconomically Distressed Environments?
Authors: Debra K Moser, Misook L Chung, Jennifer L Miller, Gia Mudd-Martin, Mary Kay Rayens, Terry A Lennie
Journal: Circulation (2019)

Introduction: Rural Appalachian Kentucky has among the lowest health literacy, contains the poorest county, reports the highest rates of mentally and physically unhealthy days, and has the most ind...
Modification of rVWF with Polysialic Acid: Biochemical and Functional Characterization in Mice with VWD.
Authors: Peter L. Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Váradi, H. Peter Matthiessen, Eva-Maria Muchitsch, Bernhard Baumgartner, Hans Peter Schwarz
Journal: Blood (2006)
Arsenic Trioxide Affects Early Stage Angiogenesis through Inhibition of CD14 Monocyte Transdifferentiation into Endothelial Cells Induced by Pleiotrophin and mCSF.
Authors: Haiming Chen, Mingjie Li, Richard A. Campbell, Melinda S. Gordon, Dror Shalitin, Cathy S. Wang, Ariana M. Berenson, Jennifer Li, Hetty Wong, James Wang, Benjamin Bonavida, James R. Berenson
Journal: Blood (2006)
CLL-1, a Receptor Expressed on Myeloid Leukemic Stem Cells, Is a Potential Target for Immunotherapy of AML
Authors: Wouter Korver, Xiaoxian Zhao, Shweta Singh, Cecile Pardoux, Jingsong Zhao, Siddhartha Sen, Monica L. Guzman, Craig T. Jordan, Eric D Hsi, Arie Abo
Journal: Blood (2008)
10分钟会诊：睡眠障碍（失眠症）
Authors: 刘秀芬, 宋建涛
Journal: BMJ (2009)

一位53岁的男性诉说他睡眠不佳已经有许多年了，而且第二天总是感到疲乏。他曾尝试口服镇静药物，有时镇静药物可有助于睡眠，但他发现药物的作用不持久，因此不愿意连续服用。他每天晚上躺在床上大约9～10小时（大约晚9点半或10点上床，早7点起床），仍然不能得到好的睡眠。每晚他的实际睡眠时间为5．5～6小时。他一夜中要醒3次，认为自己的睡眠质量很差。
A Randomized Phase IIa Study of Vorinostat in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes: Preliminary Results
Authors: Guillermo Garcia-Manero, Lewis B. Silverman, Ivana Gojo, Laura Michaelis, Simrit Parmar, Stuart L Goldberg, Hagop M. Kantarjian, Jose Garcia-Vargas, Syed Rizvi, Karl Heath, Azra Raza
Journal: Blood (2008)
Antithymocyte Globulins (ATG) as Part of the Myeloablative Conditioning (MAC) Regimen Can Reduce the Risk of Severe Graft-Vs.-Host Disease (GVHD) after Allogeneic Stem Cell Transplantation (allo-SCT) from Matched-Unrelated Donors (MUD).
Authors: Mohamad Mohty, Marie- Lorraine Balere, Gerard Socie, Noel-Jean Milpied, Norbert Ifrah, Mathieu Kuentz, Jean-Luc Harousseau, Jean-Paul Vernant, Mauricette Michallet, Agnes Buzyn, Jean-Yves Cahn, Jean-Henri Bourhis, Didier Blaise, Colette Raffoux, Helene Esperou, Ibrahim Yakoub-Agha
Journal: Blood (2008)
Wnt5a induces and maintains prostate cancer cells dormancy in bone
Authors: Dong Ren, Yuhu Dai, Qing Yang, Xin Zhang, Wei Guo, Liping Ye, Shuai Huang, Xu Chen, Yingrong Lai, Hong Du, Chuyong Lin, Xinsheng Peng, Libing Song
Journal: The Journal of Experimental Medicine (2018)

In a substantial fraction of prostate cancer (PCa) patients, bone metastasis appears after years or even decades of latency. Canonical Wnt/β-catenin signaling has been proposed to be implicated in dormancy of cancer cells. However, how these tumor cells are kept dormant and recur under control of Wnt/β-catenin signaling derived from bone microenvironment remains unknown. Here, we report that Wnt5a from osteoblastic niche induces dormancy of PCa cells in a reversible manner in vitro and in vivo via inducing Siah E3 Ubiquitin Protein Ligase 2 (SIAH2) expression, which represses Wnt/β-catenin signaling. Furthermore, this effect of Wnt5a-induced dormancy of PCa cells depends on receptor tyrosine kinase-like orphan receptor 2 (ROR2), and a negative correlation of ROR2 expression with bone metastasis-free survival is observed in PCa patients. Therefore, these results demonstrate that Wnt5a/ROR2/SIAH2 signaling axis plays a crucial role in inducing and maintaining PCa cells dormancy in bone, suggesting a potential therapeutic utility of Wnt5a via inducing dormancy of PCa cells in bone.